Updated for IRA 2026 Drug Selection Cycle

IRA Drug Price Negotiation
Intelligence Platform

Purpose-built analytics for healthcare market access teams navigating CMS drug selection, MFP modeling, and payer strategy under the Inflation Reduction Act.

Open Risk Analyzer CMS Outcome Simulator
6
Scoring dimensions
4
Integrated tools
IRA §1191
Statutory framework
PDF
Export ready
Platform Tools

Four tools. One strategy suite.

Each tool addresses a distinct phase of the IRA negotiation preparation lifecycle.

Active

IRA Negotiation Risk Analyzer

Assess your product's CMS drug selection probability with a 6-factor weighted risk model. Includes MTEP eligibility assessment, market access strategy recommendations, and payer landscape analysis. Export-ready PDF report.

Open Analyzer
Active

CMS Outcome Simulator

Model the financial impact of IRA negotiation across statutory discount tiers. Simulate MFP price scenarios, 5-year revenue trajectories, and multi-scenario revenue waterfall analysis based on WAC and Medicare utilization inputs.

Open Simulator
Active

HEOR Value Dossier Generator

Generate structured health economic and outcomes research evidence packages for CMS and commercial payer negotiations. AMCP-format dossier scaffolding, evidence gap analysis, ICER positioning, payer value narratives, and submission readiness checklist.

Open Dossier Generator
Active

Model Validator

Retrospective validation of the CMS Outcome Simulator against 2024 published Maximum Fair Prices. Pre-loaded with all 10 inaugural negotiation cycle drugs, per-drug prediction error, RMSE, bar chart, and outlier analysis for Imbruvica and Januvia.

Open Model Validator
Methodology

Built on the IRA statutory framework

All scoring models are derived directly from IRA § 1191–1198 eligibility criteria, CMS guidance documents, and established healthcare market access consulting methodology.

MTEP clock modeling
9-year (small molecule) and 13-year (biologic) eligibility thresholds per § 1192(d)
Statutory discount tier mapping
25%, 35%, and 60% MFP ceilings based on non-FAMP, modeled from WAC proxy
Multi-stakeholder payer analysis
Medicare Part D, Medicaid Best Price, and commercial spillover implications modeled together
Risk Score Interpretation
Low Risk — Score 0–39
Near-term selection unlikely. Focus on MTEP readiness planning.
Moderate Risk — Score 40–70
Active monitoring required. Begin MFP scenario modeling.
High Risk — Score 71–100
Immediate negotiation preparation protocol. Engage counsel now.